The Journal of Urology
Volume 166, Issue 4 , Pages 1316-1321, October 2001

SOCIETY OF UROLOGIC ONCOLOGY BIOTECHNOLOGY FORUM: NEW APPROACHES AND TARGETS FOR ADVANCED PROSTATE CANCER

From the Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, Department of Urological Oncology, New York Presbyterian Hospital-Weill Medical College of Cornell University, Ithaca, New York, Scott Department of Urology, Baylor College of Medicine, Houston, Texas and Department of Urology, Wayne State University, Detroit, Michigan

Purpose

We provide an overview of advances in molecular based therapeutic strategies for prostate cancer and summarize the studies presented at the Society of Urologic Oncology Biotechnology Forum in 2000.

Materials and Methods

Three promising new treatment strategies are presented, and a critique of the advantages and limitations of each is offered by a leading expert in the field.

Results

Treatment results and the current state of dendritic cell based immunotherapy, monoclonal antibody therapy and anti-apoptotic treatment approaches are presented.

Conclusions

Currently patients with advanced prostate carcinoma have expanded therapeutic options available in the form of molecular based phases II and III clinical trials.

Key Words:  prostate , prostatic neoplasms , apoptosis , biotechnology , clinical trials

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Accepted for publication May 4, 2001.Presented at annual meeting of Society of Urologic Oncology, Atlanta, Georgia, April 29, 2000.

PII: S0022-5347(05)65760-6

The Journal of Urology
Volume 166, Issue 4 , Pages 1316-1321, October 2001

Article Tools

* Image Usage & Resolution